AngioDynamics Receives FDA Clearance for NanoKnife Prostate Treatment, Enhancing Cancer Care Standards

AngioDynamics Secures FDA Clearance for Innovative Prostate Treatment

AngioDynamics, Inc., a leader in medical technology dedicated to improving vascular health and cancer therapies, achieves a significant milestone with the FDA's 510(k) clearance for its NanoKnife System, a pioneering tool designed for prostate tissue ablation. This clearance is a result of the successful PRESERVE clinical study, which rigorously assessed the system's safety and effectiveness for patients diagnosed with intermediate-risk prostate cancer. Conducted in collaboration with the Society of Urologic Oncology Clinical Trials Consortium, the study involved 121 patients across 17 clinical sites, marking a critical step forward for both AngioDynamics and the broader field of oncology.

The PRESERVE study demonstrates promising outcomes, as it meets its primary effectiveness endpoint, with 84.0% of participants remaining free from significant disease one year after the procedure. Additionally, quality of life metrics are notably favorable; 95.4% of patients maintain urinary continence, while only a modest 9% report a decrease in their ability to achieve erections sufficient for intercourse. This data reinforces AngioDynamics' commitment to providing treatments that prioritize not only the eradication of cancer but also the preservation of vital functions, which is often a crucial concern for patients facing prostate cancer interventions.

Jim Clemmer, President and CEO of AngioDynamics, expresses enthusiasm for the FDA's clearance, emphasizing the company's aspiration to position the NanoKnife System as the standard of care for prostate tumors. By selectively targeting prostate tissue, the NanoKnife aims to reduce complications traditionally associated with prostate cancer treatments. With prostate cancer representing approximately 1.5 million new cases globally, AngioDynamics’ initiative to expand access to this innovative technology through educational outreach is a vital component of its mission to redefine treatment standards and significantly enhance patient outcomes.

In addition to the recent FDA clearance, AngioDynamics remains focused on continuing its research and development efforts to broaden its portfolio of innovative cancer treatment solutions. The company's commitment to advancing medical technologies positions it as a key player in the ongoing fight against cancer, with a vision that aligns closely with the needs of patients and healthcare providers alike.

Furthermore, AngioDynamics is actively engaging in initiatives to educate healthcare professionals and patients about the NanoKnife System, ensuring that its benefits are widely understood and accessible. By prioritizing patient education and outreach, the company aims to foster a more informed patient population that can make empowered decisions regarding their prostate health.